{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T09:30:51Z","timestamp":1751275851593,"version":"3.40.4"},"reference-count":5,"publisher":"S. Karger AG","issue":"7-8","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2022]]},"abstract":"<b><i>Introduction:<\/i><\/b> The aim of this survey was to assess the efficacy and the feasibility of scalp cooling (SC) in an outpatient hematological and oncological center in a real-world setting. <b><i>Methods:<\/i><\/b> We prospectively monitored cancer patients from August 2017 to October 2019 receiving oncological treatments with SC, using the sensor-controlled system \u201cDigniCap.\u201d Effectiveness was defined by a self-estimated hair loss &#x3c; Grad 2 (&#x3c;50%) according to the Common terminology Criteria for adverse events V4.0 or not requiring a wig. Withdrawal from SC on patient\u2019s demand was considered as failure. Tolerability and safety were also evaluated. <b><i>Results:<\/i><\/b> Ninety-four patients with chemotherapy for their primary (52%) or metastatic (48%) disease had a total of 634 SC sessions. SC was well accepted with increasing experience of the nurses (withdrawal for any reason 29\/94). Among the female population (<i>N<\/i> = 85) 54% received a (neo-)adjuvant chemotherapy. Forty-eight percentages received a taxane-based therapy, 35% anthracycline-based, 17% platin compounds, and others. The overall success rate in the female sample was 72%. In the male group (<i>N<\/i> = 9), the majority had a metastatic disease (6\/9) and received a taxane-based therapy (5\/9). The rate of withdrawal by discomfort and pain was high, and the success rate was 44%. <b><i>Conclusion:<\/i><\/b> Our study confirms the satisfaction of patients with SC to prevent chemotherapy-induced alopecia. SC increases acceptance of the recommendation and administration of chemotherapy and decreases the degree of distress of patients and their treating physicians. Reimbursement remains a major issue in the out patient setting. <\/jats:p>","DOI":"10.1159\/000523759","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T22:00:43Z","timestamp":1645826443000},"page":"395-399","source":"Crossref","is-referenced-by-count":4,"title":["Scalp Cooling for Prevention of Chemotherapy-Induced Alopecia for Women and Men with Various Cancer Entities: A Two-Year Survey of an Outpatient Cancer Center in Germany"],"prefix":"10.1159","volume":"45","author":[{"given":"Sabine","family":"Keim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Retzer-Lidl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Wohlmuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Milani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0263"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4185-9"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s15015-016-2954-7"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.658966"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0332"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/523759","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/523759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:54:33Z","timestamp":1745423673000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000523759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":5,"journal-issue":{"issue":"7-8","published-online":{"date-parts":[[2022,8,4]]},"published-print":{"date-parts":[[2022,8,11]]}},"URL":"https:\/\/doi.org\/10.1159\/000523759","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"type":"print","value":"2296-5270"},{"type":"electronic","value":"2296-5262"}],"subject":[],"published":{"date-parts":[[2022]]}}}